Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma

Abstract Objectives Serologic testing for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in potential donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) may not be performed until after blood donation. A hospital-based recruitment program for CCP may...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical pathology 2021-04, Vol.155 (4), p.515-521
Main Authors: Balcerek, Joanna, Trejo, Evelin, Levine, Kendall, Couey, Paul, Kornberg, Zoe V, Rogine, Camille, Young, Charlotte, Li, P Jonathan, Shy, Brian R, Taylor, Jordan E, Bakhtary, Sara, Friedlander, Terence, Lynch, Kara L, Bern, Caryn, Esensten, Jonathan H
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies
Blood & organ donations
Blood banks
Blood donors
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - therapy
COVID-19 Serological Testing - methods
Diagnosis
Female
Hospitals
Humans
Immunization, Passive
Immunoglobulin G
Immunoglobulin M
Linear Models
Male
Medical records
Middle Aged
Original
Patients
Polymerase chain reaction
San Francisco
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Tissue and Organ Procurement - methods
Tissue and Organ Procurement - organization & administration
Tissue Donors
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives Serologic testing for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in potential donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) may not be performed until after blood donation. A hospital-based recruitment program for CCP may be an efficient way to identify potential donors prospectively Methods Patients who recovered from known or suspected COVID-19 were identified and recruited through medical record searches and public appeals in March and April 2020. Participants were screened with a modified donor history questionnaire and, if eligible, were asked for consent and tested for SARS-CoV-2 antibodies (IgG and IgM). Participants positive for SARS-CoV-2 IgG were referred for CCP collection. Results Of 179 patients screened, 128 completed serologic testing and 89 were referred for CCP donation. IgG antibodies to SARS-CoV-2 were detected in 23 of 51 participants with suspected COVID-19 and 66 of 77 participants with self-reported COVID-19 confirmed by polymerase chain reaction (PCR). The anti–SARS-CoV-2 IgG level met the US Food and Drug Administration criteria for “high-titer” CCP in 39% of participants confirmed by PCR, as measured by the Ortho VITROS IgG assay. A wide range of SARS-CoV-2 IgG levels were observed. Conclusions A hospital-based CCP donor recruitment program can prospectively identify potential CCP donors. Variability in SARS-CoV-2 IgG levels has implications for the selection of CCP units for transfusion.
ISSN:0002-9173
1943-7722
DOI:10.1093/ajcp/aqaa268